Background The impact of treatment delay in stable patients with pulmonary arterial hypertension (PAH) remains unaddressed. Methods This meta-analysis included six datasets of PAH therapies with randomized-controlled trials (RCT) and corresponding open-label extension (OLE) studies. We evaluated the change in 6MWD at 1 year in the OLE studies by active treatment versus ex-placebo group. The ex-placebo group (i.e., the patients randomized to placebo in the RCT and ultimately treated with active therapy in the OLE) represented the “delay-in-treatment” population. Results Patients with a treatment delay of 12–16 weeks in PAH targeted therapy had an improvement in 6-minute walk distance (6MWD) test at 1 year, but this improvement did not amount to the same degree of improvement as their initially treated counterparts. The difference in 6MWD was 15 m to 20 m at 1 year. Conclusion A short-term delay in PAH targeted therapy may adversely affect functional capacity in patients with PAH. This meta-analysis provides some insight as to whether earlier treatment would benefit stable patients with PAH.

The impact of delayed treatment on 6-minute walk distance test in patients with pulmonary arterial hypertension. a meta-analysis / Vizza, C. D.; Badagliacca, R.; Messick, C. R.; Rao, Y.; Nelsen, A. C.; Benza, R. L.. - In: INTERNATIONAL JOURNAL OF CARDIOLOGY. - ISSN 0167-5273. - 254:(2018), pp. 299-301. [10.1016/j.ijcard.2017.12.016]

The impact of delayed treatment on 6-minute walk distance test in patients with pulmonary arterial hypertension. a meta-analysis

Vizza C. D.
;
Badagliacca R.;
2018

Abstract

Background The impact of treatment delay in stable patients with pulmonary arterial hypertension (PAH) remains unaddressed. Methods This meta-analysis included six datasets of PAH therapies with randomized-controlled trials (RCT) and corresponding open-label extension (OLE) studies. We evaluated the change in 6MWD at 1 year in the OLE studies by active treatment versus ex-placebo group. The ex-placebo group (i.e., the patients randomized to placebo in the RCT and ultimately treated with active therapy in the OLE) represented the “delay-in-treatment” population. Results Patients with a treatment delay of 12–16 weeks in PAH targeted therapy had an improvement in 6-minute walk distance (6MWD) test at 1 year, but this improvement did not amount to the same degree of improvement as their initially treated counterparts. The difference in 6MWD was 15 m to 20 m at 1 year. Conclusion A short-term delay in PAH targeted therapy may adversely affect functional capacity in patients with PAH. This meta-analysis provides some insight as to whether earlier treatment would benefit stable patients with PAH.
2018
6-minute walk distance; delayed treatment; early treatment; functional capacity; pulmonary arterial hypertension
01 Pubblicazione su rivista::01a Articolo in rivista
The impact of delayed treatment on 6-minute walk distance test in patients with pulmonary arterial hypertension. a meta-analysis / Vizza, C. D.; Badagliacca, R.; Messick, C. R.; Rao, Y.; Nelsen, A. C.; Benza, R. L.. - In: INTERNATIONAL JOURNAL OF CARDIOLOGY. - ISSN 0167-5273. - 254:(2018), pp. 299-301. [10.1016/j.ijcard.2017.12.016]
File allegati a questo prodotto
File Dimensione Formato  
Vizza_Impact_2018.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 304.08 kB
Formato Adobe PDF
304.08 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1622051
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 14
social impact